Michela Cortesi
Overview
Explore the profile of Michela Cortesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cortesi M, Guerrini R, Roccatello C, Pacifico S, Albanese V, Ulivi P, et al.
Eur J Nucl Med Mol Imaging
. 2025 Feb;
PMID: 40000458
No abstract available.
2.
Cortesi M, Bravaccini S, Ravaioli S, Petracci E, Angeli D, Tumedei M, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594707
Background: Adjuvant trastuzumab is the standard of care for HER2+ breast cancer (BC) patients. However, >50% of patients become resistant. This study aimed at the identification of the molecular factors...
3.
Masciale V, Banchelli F, Grisendi G, Samarelli A, Raineri G, Rossi T, et al.
J Biol Chem
. 2024 Nov;
300(12):107994.
PMID: 39547513
Cancer stem cells (CSCs) may be dedifferentiated somatic cells following oncogenic processes, representing a subpopulation of cells able to promote tumor growth with their capacities for proliferation and self-renewal, inducing...
4.
Cortesi M, Rossino G, Chakrabarty A, Rossi D
Front Med (Lausanne)
. 2023 Sep;
10:1268976.
PMID: 37663659
No abstract available.
5.
Tumedei M, Piccinini F, Azzali I, Pirini F, Bravaccini S, De Matteis S, et al.
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373066
The majority of patients with Follicular Lymphoma (FL) experience subsequent phases of remission and relapse, making the disease "virtually" incurable. To predict the outcome of FL patients at diagnosis, various...
6.
Miserocchi G, Bocchini M, Cortesi M, Arienti C, De Vita A, Liverani C, et al.
Front Immunol
. 2023 Apr;
14:1171141.
PMID: 37033986
Tumors are complex and heterogeneous diseases characterized by an intricate milieu and dynamically in connection with surrounding and distant tissues. In the last decades, great efforts have been made to...
7.
Pirini F, Cortesi M, Tumedei M, Zanoni M, Ravaioli S, Bravaccini S
Front Cell Dev Biol
. 2023 Jan;
10:1048360.
PMID: 36684442
The role of the intestinal microbiota in the promotion, progression, and response to therapies is gaining importance, but recent studies confirm the presence of microbiota also in the tumor, thus...
8.
Bravaccini S, Nicolini F, Zanoni M, Gaimari A, Cerchione C, Maltoni R, et al.
Transl Oncol
. 2022 Sep;
26:101541.
PMID: 36119944
Zhang et al. reported the impact of different risk factors and comorbidities in COVID-19 lethality. The authors observed that the odds of dying by COVID-19 in cancer patients decrease with...
9.
Cortesi M, Zanoni M, Maltoni R, Ravaioli S, Tumedei M, Pirini F, et al.
Expert Opin Ther Targets
. 2022 Aug;
26(7):593-602.
PMID: 35962580
Introduction: Breast cancer (BC) is the most common diagnosed cancer and the second leading cause of cancer-associated death in women, with the triple negative (TNBC) subtype being characterized by the...
10.
Tesei A, Cortesi M, Bedeschi M, Marino N, Rossino G, Listro R, et al.
Molecules
. 2022 Jul;
27(14).
PMID: 35889200
Different pathological conditions, including viral infections and cancer, can have a massive impact on the endoplasmic reticulum (ER), causing severe damage to the cell and exacerbating the disease. In particular,...